This Phase II study, sponsored by Washington University School of Medicine, aims to improve leukemia-free survival rates in patients with refractory acute myeloid leukemia (AML) through the use of cytokine-induced memory-like NK cell adoptive therapy following haploidentical donor hematopoietic cell transplantation. The target market includes high-risk AML patients, a segment with significant unmet medical needs. If successful, this therapy could position itself favorably against existing treatments, particularly in a landscape where novel immunotherapies are gaining traction. The collaboration with entities such as the NIH and ImmunityBio, Inc. suggests a strong backing that may enhance credibility and facilitate future commercialization efforts. Diligence should focus on competitive landscape analysis, particularly regarding other NK cell therapies and their clinical outcomes.